Mesoblast (MESO) Other Non Operating Income (2014 - 2023)
Mesoblast (MESO) posted Other Non Operating Income of $10.3 million for Q4 2025, up 596.67% sequentially from $1.5 million in Q4 2023.
Analysis
Mesoblast (MESO) Other Non Operating Income (2014 - 2023) Analysis & Trends
Mesoblast has reported Other Non Operating Income for 9 years, with the latest figure at $10.3 million in Q4 2025.
- Quarterly Other Non Operating Income changed N/A year-over-year to $10.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.3 million (changed N/A YoY) and the FY2022 annual result came in at $5.9 million, up 486.88% from the prior year.
- Other Non Operating Income grew to $10.3 million in Q4 2025 per MESO's latest filing, from $1.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $10.3 million in Q4 2025 and troughed at -$401000.0 in Q3 2022.
- A 4-year average of $2.2 million and a median of $1.5 million in 2022 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 138.05% in 2021, down 185.54% in 2021.
- Over 4 years, Other Non Operating Income stood at $2.2 million in 2021, then plunged by 31.55% to $1.5 million in 2022, then changed by 0.0% to $1.5 million in 2023, then soared by 596.67% to $10.3 million in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $10.3 million, $1.5 million, and $1.5 million for Q4 2025, Q4 2023, and Q1 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -517,000.00 |
| Dec 31, 2022 | -311,000.00 |
| Sep 30, 2022 | -401,000.00 |
| Jun 30, 2022 | 526,000.00 |
| Mar 31, 2022 | 896,000.00 |
| Dec 31, 2021 | 2.15 Mn |
| Sep 30, 2018 | -151,000.00 |
| Sep 30, 2017 | 75,000.00 |
| Sep 30, 2016 | -9,000.00 |
| Sep 30, 2015 | -257,000.00 |
| Sep 30, 2014 | 4.63 Mn |